These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunohistochemical detection of the c-met proto-oncogene product in the congenital melanocytic nevus of an infant with neurocutaneous melanosis. Takayama H; Nagashima Y; Hara M; Takagi H; Mori M; Merlino G; Nakazato Y J Am Acad Dermatol; 2001 Mar; 44(3):538-40. PubMed ID: 11209133 [TBL] [Abstract][Full Text] [Related]
23. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Lim YH; Ovejero D; Sugarman JS; Deklotz CM; Maruri A; Eichenfield LF; Kelley PK; Jüppner H; Gottschalk M; Tifft CJ; Gafni RI; Boyce AM; Cowen EW; Bhattacharyya N; Guthrie LC; Gahl WA; Golas G; Loring EC; Overton JD; Mane SM; Lifton RP; Levy ML; Collins MT; Choate KA Hum Mol Genet; 2014 Jan; 23(2):397-407. PubMed ID: 24006476 [TBL] [Abstract][Full Text] [Related]
24. Malignant melanoma arising from an NRAS-mutated medium-sized congenital melanocytic nevus. Kiyohara T; Takata M; Itoh H; Kawami K; Ido H; Ishida H; Kumakiri M J Dermatol; 2012 Dec; 39(12):1034-5. PubMed ID: 22452623 [No Abstract] [Full Text] [Related]
25. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Küsters-Vandevelde HV; Willemsen AE; Groenen PJ; Küsters B; Lammens M; Wesseling P; Djafarihamedani M; Rijntjes J; Delye H; Willemsen MA; van Herpen CM; Blokx WA Acta Neuropathol Commun; 2014 Apr; 2():41. PubMed ID: 24713450 [TBL] [Abstract][Full Text] [Related]
26. Detection of a multilineage mosaic NRAS mutation c.181C>A (p.Gln61Lys) in an individual with a complex congenital nevus syndrome. Ulrich M; Tinschert S; Siebert E; Franke I; Tüting T; Ulrich J; Schanze D; Wieland I; Zenker M Pigment Cell Melanoma Res; 2019 May; 32(3):470-473. PubMed ID: 30548225 [No Abstract] [Full Text] [Related]
27. Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy. Ruan Y; Kovalchuk A; Jayanthan A; Lun X; Nagashima Y; Kovalchuk O; Wright JR; Pinto A; Kirton A; Anderson R; Narendran A Neuro Oncol; 2015 Jun; 17(6):822-31. PubMed ID: 25395461 [TBL] [Abstract][Full Text] [Related]
28. Neurocutaneous Melanocytosis and Leptomeningeal Melanoma. Mitre V; Heym K; Clark GD; Venkatramani R J Pediatr Hematol Oncol; 2021 Mar; 43(2):e195-e197. PubMed ID: 31764519 [TBL] [Abstract][Full Text] [Related]
29. Neuropsychiatric systemic lupus erythematosus in a girl with neurocutaneous melanosis caused by a somatic mutation in NRAS. Inoguchi T; Takenouchi T; Yamazaki F; Kondo Y; Mitamura H; Kosaki K; Takahashi T Rheumatology (Oxford); 2022 Aug; 61(8):e224-e226. PubMed ID: 35238342 [No Abstract] [Full Text] [Related]
31. Genomic analysis of adult case of ocular surface giant congenital melanocytic nevus and associated clinicopathological findings. McGrath LA; Palmer JM; Stark A; Glasson W; Warrier SK; Whitehead K; Hamilton H; Brooks K; Johansson PA; Hayward NK Ophthalmic Genet; 2020 Dec; 41(6):616-620. PubMed ID: 32814477 [TBL] [Abstract][Full Text] [Related]
32. Significant improvement of a nevus spilus-type congenital melanocytic nevus with oral selumetinib. Berna R; Hasbun T; Adams D; Moon AT; Treat JR Pediatr Dermatol; 2024; 41(5):936-937. PubMed ID: 38886992 [TBL] [Abstract][Full Text] [Related]
33. The risk of melanoma and neurocutaneous melanosis associated with congenital melanocytic nevi. Shah KN Semin Cutan Med Surg; 2010 Sep; 29(3):159-64. PubMed ID: 21051009 [TBL] [Abstract][Full Text] [Related]